HUP0103485A2 - A kivánt fehérjék túlexpressziója eukarióta sejtekben, a D1 ciklin túlexpressziójával vezérelve - Google Patents
A kivánt fehérjék túlexpressziója eukarióta sejtekben, a D1 ciklin túlexpressziójával vezérelveInfo
- Publication number
- HUP0103485A2 HUP0103485A2 HU0103485A HUP0103485A HUP0103485A2 HU P0103485 A2 HUP0103485 A2 HU P0103485A2 HU 0103485 A HU0103485 A HU 0103485A HU P0103485 A HUP0103485 A HU P0103485A HU P0103485 A2 HUP0103485 A2 HU P0103485A2
- Authority
- HU
- Hungary
- Prior art keywords
- cyclin
- overexpression
- selected protein
- nucleic acid
- acid encoding
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract 10
- 102000004169 proteins and genes Human genes 0.000 title abstract 10
- 210000003527 eukaryotic cell Anatomy 0.000 title abstract 3
- 230000002018 overexpression Effects 0.000 title 2
- 102000016736 Cyclin Human genes 0.000 title 1
- 108050006400 Cyclin Proteins 0.000 title 1
- 230000001404 mediated effect Effects 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 abstract 4
- 108020004707 nucleic acids Proteins 0.000 abstract 4
- 150000007523 nucleic acids Chemical class 0.000 abstract 4
- 108090000259 Cyclin D Proteins 0.000 abstract 3
- 102000003951 Erythropoietin Human genes 0.000 abstract 3
- 108090000394 Erythropoietin Proteins 0.000 abstract 3
- 210000004027 cell Anatomy 0.000 abstract 3
- 229940105423 erythropoietin Drugs 0.000 abstract 3
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 abstract 3
- 102000008108 Osteoprotegerin Human genes 0.000 abstract 2
- 108010035042 Osteoprotegerin Proteins 0.000 abstract 2
- 229940039781 leptin Drugs 0.000 abstract 2
- XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 abstract 2
- 102000003910 Cyclin D Human genes 0.000 abstract 1
- 102000016267 Leptin Human genes 0.000 abstract 1
- 108010092277 Leptin Proteins 0.000 abstract 1
- -1 OPG-Fc Chemical compound 0.000 abstract 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 abstract 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 abstract 1
- 210000004962 mammalian cell Anatomy 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
A találmány tárgyát fehérje expresszálásra használható eukariótasejtek képezik, amik az alábbiakat tartalmazzák: a) egy D ciklintkódoló beépített nukleinsavat és b) egy kiválasztott fehérjét kódolóbeépített nukleinsavat, és a kiválasztott fehérjét a sejtbenexpresszáltatják. A találmány tárgyát képezi továbbá a kiválasztottfehérje expresszálási eljárása, aminek során a) egy eukarióta sejtbebeépítenek egy D ciklin génterméket kódoló nukleinsavat, valamint akiválasztott fehérjét kódoló nukleinsavat; b) a sejtet olyankörülmények között tenyésztik, amik lehetővé teszik a kiválasztottfehérje expresszióját, és c) izolálják a kiválasztott fehérjét. Asejtek előnyösen emlős sejtek, amik közül leginkább a CHO sejteketrészesítik előnyben. A D ciklin géntermék előnyösen humán eredetű. Akiválasztott megfelelő fehérjék közé tartozik az eritropoietin (EPO),az oszteoprotegerin (OPG), az OPG-Fc, a leptin, az Fc-leptin és az újeritropoietin serkentő fehérje (NESP). Ó
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9608698P | 1998-08-11 | 1998-08-11 | |
| US60/096,086 | 1998-08-11 | ||
| US09/371,309 US6210924B1 (en) | 1998-08-11 | 1999-08-10 | Overexpressing cyclin D 1 in a eukaryotic cell line |
| US09/371,309 | 1999-08-10 | ||
| PCT/US1999/018213 WO2000009714A1 (en) | 1998-08-11 | 1999-08-11 | Overexpression of desired proteins in eukaryotic cells mediated by cyclin d1 overexpression |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| HUP0103485A2 true HUP0103485A2 (hu) | 2002-01-28 |
| HUP0103485A3 HUP0103485A3 (en) | 2010-01-28 |
| HU230247B1 HU230247B1 (hu) | 2015-11-30 |
Family
ID=22255220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0103485A HU230247B1 (hu) | 1998-08-11 | 1999-08-11 | A kívánt fehérjék túlexpressziója eukarióta sejtekben, a D1 ciklin túlexpressziójával vezérelve |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US6210924B1 (hu) |
| EP (1) | EP1105507B1 (hu) |
| JP (1) | JP4562915B2 (hu) |
| KR (1) | KR100502701B1 (hu) |
| CN (1) | CN1151263C (hu) |
| AT (1) | ATE374827T1 (hu) |
| AU (1) | AU747640B2 (hu) |
| CA (1) | CA2338820C (hu) |
| CY (1) | CY1106987T1 (hu) |
| DE (1) | DE69937243T2 (hu) |
| DK (1) | DK1105507T3 (hu) |
| ES (1) | ES2291038T3 (hu) |
| HU (1) | HU230247B1 (hu) |
| PT (1) | PT1105507E (hu) |
| WO (1) | WO2000009714A1 (hu) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020090646A1 (en) * | 2000-05-03 | 2002-07-11 | Amgen Inc. | Calcitonin-related molecules |
| EP1414517A4 (en) * | 2001-06-26 | 2008-02-06 | Photomed Technologies Inc | MULTIPLE WAVELENGTH ILLUMINATOR |
| CN1547486A (zh) | 2001-06-26 | 2004-11-17 | 抗opgl抗体 | |
| KR100427299B1 (ko) * | 2001-08-10 | 2004-04-14 | 한국생명공학연구원 | 인체 골 재흡수 억제인자（ｈＯＰＧ）를 생산하는 재조합플라스미드 ｐＧＨＯＰＧ（ＫＣＴＣ １０１９ＢＰ） |
| EP1494714A4 (en) | 2002-04-05 | 2008-03-05 | Amgen Inc | HUMAN ANTI-OPGL NEUTRALIZING ANTIBODIES AS SELECTIVE OPGL PATH HEMMER |
| EA018072B1 (ru) | 2002-09-06 | 2013-05-30 | Амджен Инк. | Антитело к рецептору интерлейкина-1 типа 1 (il-1r1) и его применение |
| MY146381A (en) | 2004-12-22 | 2012-08-15 | Amgen Inc | Compositions and methods relating relating to anti-igf-1 receptor antibodies |
| EP1739179A1 (en) * | 2005-06-30 | 2007-01-03 | Octapharma AG | Serum-free stable transfection and production of recombinant human proteins in human cell lines |
| TW200736277A (en) | 2005-11-14 | 2007-10-01 | Amgen Inc | RANKL antibody-PTH/PTHrP chimeric molecules |
| KR20090074040A (ko) | 2006-09-13 | 2009-07-03 | 아보트 러보러터리즈 | 세포 배양의 개선 |
| EP2500416A1 (en) | 2006-09-13 | 2012-09-19 | Abbott Laboratories | Cell culture improvements |
| AU2008214386B2 (en) * | 2007-02-02 | 2013-09-19 | Amgen Inc | Hepcidin and hepcidin antibodies |
| US7982016B2 (en) | 2007-09-10 | 2011-07-19 | Amgen Inc. | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
| JO3382B1 (ar) | 2008-12-23 | 2019-03-13 | Amgen Inc | أجسام مضادة ترتبط مع مستقبل cgrp بشري |
| WO2011063348A1 (en) | 2009-11-23 | 2011-05-26 | Amgen Inc. | Monomeric antibody fc |
| EP2591121B1 (en) * | 2010-07-05 | 2018-01-24 | Lonza Ltd | Production cell line |
| CA2825894C (en) | 2011-02-02 | 2021-11-30 | Amgen Inc. | Prognosis of cancer using a circulating biomarker |
| EP2847219A1 (en) | 2012-05-07 | 2015-03-18 | Amgen Inc. | Anti-erythropoietin antibodies |
| WO2014004549A2 (en) | 2012-06-27 | 2014-01-03 | Amgen Inc. | Anti-mesothelin binding proteins |
| AU2014318017B2 (en) | 2013-09-05 | 2020-02-06 | Amgen Inc. | Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles |
| US10435464B1 (en) | 2014-09-05 | 2019-10-08 | Coherus Biosciences, Inc. | Methods for making recombinant proteins |
| TW201620938A (zh) | 2014-09-15 | 2016-06-16 | 安美基公司 | 雙特異性抗cgrp受體/pac1受體抗原結合蛋白質及其用途 |
| JP6749898B2 (ja) | 2014-10-15 | 2020-09-02 | アムジエン・インコーポレーテツド | 宿主細胞における異種由来遺伝子の発現を改善するためのプロモーター及び調節エレメント |
| CN111018987B (zh) | 2014-12-05 | 2023-11-21 | 鸿运华宁（杭州）生物医药有限公司 | 一种能与人内皮素受体特异性结合的抗体及其应用 |
| US10358497B2 (en) | 2015-09-29 | 2019-07-23 | Amgen Inc. | Methods of treating cardiovascular disease with an ASGR inhibitor |
| US11098310B2 (en) | 2016-01-27 | 2021-08-24 | Just-Evotec Biologics, Inc. | Expression from transposon-based vectors and uses |
| ES2823173T3 (es) | 2016-01-27 | 2021-05-06 | Just Biotherapeutics Inc | Promotor híbrido y usos del mismo |
| US11261462B2 (en) | 2016-01-27 | 2022-03-01 | Just-Evotec Biologics, Inc. | Inducible expression from transposon-based vectors and uses |
| TWI826351B (zh) | 2016-05-31 | 2023-12-21 | 大陸商鴻運華寧（杭州）生物醫藥有限公司 | Ｒ抗體,其藥物組合物及其應用 |
| EP3576789A4 (en) | 2017-02-01 | 2020-11-25 | Centrymed Pharmaceuticals Inc. | MONOMER HUMAN IGG1-FC AND BISPECIFIC ANTIBODIES |
| CN110305211A (zh) | 2018-03-20 | 2019-10-08 | 鸿运华宁（杭州）生物医药有限公司 | Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用 |
| CN110357959B (zh) | 2018-04-10 | 2023-02-28 | 鸿运华宁（杭州）生物医药有限公司 | Gcgr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用 |
| MA52490A (fr) | 2018-05-01 | 2021-03-10 | Amgen Inc | Anticorps présentant des profils de glycane modulés |
| CN110655577A (zh) | 2018-06-13 | 2020-01-07 | 鸿运华宁（杭州）生物医药有限公司 | APJ抗体及其与Elabela的融合蛋白质，以及其药物组合物和应用 |
| US20220227888A1 (en) | 2019-06-07 | 2022-07-21 | Amgen Inc. | Bispecific binding constructs with selectively cleavable linkers |
| CN112239507A (zh) | 2019-07-17 | 2021-01-19 | 鸿运华宁（杭州）生物医药有限公司 | ETA抗体与TGF-β Trap的融合蛋白质，以及其药物组合物和应用 |
| CN112521501A (zh) | 2019-09-18 | 2021-03-19 | 鸿运华宁（杭州）生物医药有限公司 | Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用 |
| AU2021283933A1 (en) | 2020-06-04 | 2023-01-05 | Amgen Inc. | Bispecific binding constructs |
| CN116783217A (zh) | 2020-12-03 | 2023-09-19 | 安进公司 | 具有多个结合结构域的免疫球蛋白构建体 |
| CN115141276A (zh) | 2021-03-31 | 2022-10-04 | 鸿运华宁（杭州）生物医药有限公司 | 一种能与人内皮素受体特异性结合的抗体及其在糖尿病肾病和慢性肾病治疗中的应用 |
| CA3221250A1 (en) | 2021-06-04 | 2022-12-08 | Amgen Research (Munich) Gmbh | T cell engager molecules and uses thereof |
| CN113698466B (zh) * | 2021-07-30 | 2023-07-14 | 山东农业大学 | Ccnd1在制备禽反转录病毒生产增强剂中的应用 |
| WO2024092033A1 (en) | 2022-10-26 | 2024-05-02 | Amgen Inc. | Multispecific molecules for clearance of immunoglobulins in the treatment of autoantibody-induced diseases |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4703008A (en) | 1983-12-13 | 1987-10-27 | Kiren-Amgen, Inc. | DNA sequences encoding erythropoietin |
| IL79176A (en) | 1985-06-20 | 1992-06-21 | Kirin Amgen Inc | Process for the recovery of erythropoietin from a fluid |
| US5013718A (en) | 1986-11-21 | 1991-05-07 | Amgen, Inc. | Method for treating iron overload using EPO |
| WO1991005867A1 (en) | 1989-10-13 | 1991-05-02 | Amgen Inc. | Erythropoietin isoforms |
| JPH06117187A (ja) | 1992-10-08 | 1994-04-26 | Iseki Tory Tech Inc | シールド掘削機 |
| US5514571A (en) | 1993-08-05 | 1996-05-07 | University Technologies International Inc. | Cyclin D1 negative regulatory activity |
| US5521066A (en) | 1993-09-13 | 1996-05-28 | Bristol-Myers Squibb Company | Periplasmic membrane-bound system for detecting protein-protein interactions |
| AU1552995A (en) | 1993-12-17 | 1995-07-03 | Spinal Cord Society | Method for inducing dna synthesis in neurons |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| EP0832220A1 (en) | 1995-06-07 | 1998-04-01 | Amgen Inc. | Ob protein compositions and method |
| PT865294E (pt) | 1995-08-17 | 2004-07-30 | Amgen Inc | Processo para a reducao ou a manutencao de niveis reduzidos de lipidos no sangue utilizando composicoes de proteina ob |
| SI0866720T1 (en) | 1995-11-22 | 2004-10-31 | Amgen Inc. | Ob protein for increasing lean tissue mass |
| US6369027B1 (en) | 1995-12-22 | 2002-04-09 | Amgen Inc. | Osteoprotegerin |
| GB9608143D0 (en) * | 1996-04-19 | 1996-06-26 | Ver Nl Kanker Inst | Assay |
-
1999
- 1999-08-10 US US09/371,309 patent/US6210924B1/en not_active Expired - Lifetime
- 1999-08-11 EP EP99942098A patent/EP1105507B1/en not_active Expired - Lifetime
- 1999-08-11 ES ES99942098T patent/ES2291038T3/es not_active Expired - Lifetime
- 1999-08-11 DE DE69937243T patent/DE69937243T2/de not_active Expired - Lifetime
- 1999-08-11 AU AU55546/99A patent/AU747640B2/en not_active Expired
- 1999-08-11 HU HU0103485A patent/HU230247B1/hu unknown
- 1999-08-11 CN CNB998118990A patent/CN1151263C/zh not_active Expired - Lifetime
- 1999-08-11 JP JP2000565148A patent/JP4562915B2/ja not_active Expired - Lifetime
- 1999-08-11 AT AT99942098T patent/ATE374827T1/de active
- 1999-08-11 WO PCT/US1999/018213 patent/WO2000009714A1/en active IP Right Grant
- 1999-08-11 CA CA002338820A patent/CA2338820C/en not_active Expired - Lifetime
- 1999-08-11 DK DK99942098T patent/DK1105507T3/da active
- 1999-08-11 PT PT99942098T patent/PT1105507E/pt unknown
- 1999-08-11 KR KR10-2001-7001843A patent/KR100502701B1/ko not_active IP Right Cessation
-
2007
- 2007-11-08 CY CY20071101438T patent/CY1106987T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CY1106987T1 (el) | 2012-09-26 |
| JP2003524378A (ja) | 2003-08-19 |
| US6210924B1 (en) | 2001-04-03 |
| PT1105507E (pt) | 2007-12-07 |
| ATE374827T1 (de) | 2007-10-15 |
| ES2291038T3 (es) | 2008-02-16 |
| EP1105507A1 (en) | 2001-06-13 |
| KR20020013462A (ko) | 2002-02-20 |
| KR100502701B1 (ko) | 2005-07-22 |
| AU747640B2 (en) | 2002-05-16 |
| CA2338820A1 (en) | 2000-02-24 |
| DE69937243T2 (de) | 2008-07-03 |
| CN1151263C (zh) | 2004-05-26 |
| HUP0103485A3 (en) | 2010-01-28 |
| CN1322253A (zh) | 2001-11-14 |
| DK1105507T3 (da) | 2007-11-05 |
| HU230247B1 (hu) | 2015-11-30 |
| AU5554699A (en) | 2000-03-06 |
| EP1105507B1 (en) | 2007-10-03 |
| JP4562915B2 (ja) | 2010-10-13 |
| CA2338820C (en) | 2005-10-18 |
| WO2000009714A1 (en) | 2000-02-24 |
| WO2000009714A9 (en) | 2000-05-18 |
| DE69937243D1 (de) | 2007-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0103485A2 (hu) | A kivánt fehérjék túlexpressziója eukarióta sejtekben, a D1 ciklin túlexpressziójával vezérelve | |
| CN108707604B (zh) | 表皮干细胞中采用CRISPR-Cas系统进行CNE10基因敲除 | |
| Yang et al. | Roles of DNA topoisomerases in simian virus 40 DNA replication in vitro. | |
| Gudas | The induction of protein X in DNA repair and cell division mutants of Escherichia coli | |
| NZ504185A (en) | Expression of endogenous genes by non-homologous recombination of a vector construct with cellular DNA | |
| WO2000027994A3 (en) | Chlamydia pneumoniae genome sequence | |
| EP1757689A3 (en) | Mammalian apoptosis inhibitor protein gene family, primers, probes and detection methods | |
| EP1555319A3 (en) | Modified nucleic acid sequences and method to increasing mRNA levels and protein expression in cell systems | |
| MXPA03010077A (es) | Abonadora de siembra a voleo con deflector movible. | |
| WO2002092764A3 (en) | Transgenic animal model of bone mass modulation | |
| AU2001230883A1 (en) | Human genome-derived single exon nucleic acid probes useful for analysis of gene expression in human hela cells or other human cervical epithelial cells | |
| AU682140B2 (en) | Multidrug resistance gene | |
| DE3851613T2 (de) | Co-Expression in eukaryontischen Zellen. | |
| HUP9900899A2 (hu) | Idegrendszeri eredetű magzati sejtvonalak felhasználása a transzplantációs terápiában | |
| EP1690939B8 (en) | Novel G protein-coupled receptor proteins | |
| DE69808743D1 (en) | Netrinrezeptoren | |
| CA2281895A1 (en) | Ikb kinases | |
| DE69928395D1 (de) | Cyclin-e2 proteine und dafür kodierende gene | |
| AU5559499A (en) | Identification of the gene causing the mouse scurfy phenotype and its human ortholog | |
| WO2000008157A3 (en) | Human anion transporter genes atnov | |
| AUPM772494A0 (en) | Improvements in production of proteins in host cells | |
| AU3205600A (en) | Method and kit for early cancer prediction | |
| AU4917300A (en) | Method for producing a recombinant protein | |
| WO2002074921A3 (en) | Methods for isolating proteins expressed by dendritic cells | |
| CN113980113B (zh) | Kcnq4功能增强型突变体及其在治疗听力损失中的应用 |